RT Journal Article
SR Electronic
T1 Use of whole genome sequencing to identify low-frequency mutations in COVID-19 patients treated with remdesivir
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.11.20.22282552
DO 10.1101/2022.11.20.22282552
A1 Nirmalarajah, Kuganya
A1 Maguire, Finlay
A1 Yim, Winfield
A1 Aftanas, Patryk
A1 Li, Angel X.
A1 Shigayeva, Altynay
A1 Yip, Lily
A1 Zhong, Xi Zoe
A1 McGeer, Allison J.
A1 Muberka, Samira
A1 Kozak, Robert
YR 2022
UL http://medrxiv.org/content/early/2022/11/22/2022.11.20.22282552.abstract
AB Background We investigate the effects of remdesivir (RDV) treatment on intra-host SARS-CoV-2 diversity and low-frequency mutations in moderately ill hospitalized COVID-19 patients and compare them to patients without RDV treatment.Methods Sequential collections of nasopharyngeal and mid-turbinate swabs were obtained from 16 patients with and 31 patients without RDV treatment. A total of 113 samples were sequenced and mutation analyses were performed.Results We did not identify any drug resistant mutations during RDV therapy. In genes encoding and associated with the replication complex, low-frequency minority variants that do not reach fixation within the sampling period were detected in 6/16 (37.5%) and 14/31 (45%) patients with and without RDV treatment respectively. We did not detect significant differences in within-host diversity and positive selection between the RDV-treated and untreated groups.Conclusions Minimal intra-host variability and stochastic low-frequency variants detected in moderately ill patients suggests little selective pressure in patients receiving short courses of RDV. Patients undergoing short regimens of RDV therapy should continue to be monitored.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Canadian Institutes of Health Research (CIHR No. 177701, No. 174925), the Canadian COVID-19 Genomics Network, and the McLaughlin Fund. K.N. is supported by awards from the University of Toronto and the Department of Laboratory Medicine and Pathobiology. R.K. is supported by the Coronavirus Variants Rapid Response Network and the Canadian Institutes of Health Research (CIHR No. 480722). F.M. is supported by awards from Dalhousie University, Natural Sciences and Engineering Research Council of Canada, Social Sciences and Humanities Research Council of Canada, and the Canadian Institutes of Health Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Sunnybrook Research Institute gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors